The tweet was deleted by the author.
But we saved everything 🙂.
Tenaya Therapeutics announced plans to deliver a late breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) conference.
The presentation will feature new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial evaluating TN-401. This update is expected to provide insight into the ongoing development of TN-401 and Tenaya Therapeutics' broader efforts to advance gene therapies. Additional presentations by the company are also scheduled at the event.